With the rapid expansion of incretin-based therapies, selecting the optimal agent for obesity and type 2 diabetes has become increasingly complex. From single GLP-1 agonists and dual GLP-1/GIP receptor co-agonists to emerging oral formulations, clinicians face evolving choices around efficacy, tolerability, cost, and patient adherence.In this high-yield session, we examine how to tailor therapy based on clinical profile, weight-loss targets, and metabolic goals. The discussion focuses on practical decision-making: comparing head-to-head outcomes, navigating gastrointestinal side effects, managing plateau phases, and applying structured protocols for transitioning patients safely between injectable and oral agents.